Biotechnology firm raising $30M to advance treatment for Parkinson’s, neurodegenerative disease
A biotechnology company that has licensed a drug for the treatment of neurodegenerative disease amyotrophic lateral sclerosis, or Lou Gehrig’s disease, in phase 3 development with Biogen Idec (NASDAQ:BIIB) is raising $30 million to develop its product pipeline. The financing is being done in two tranches of $15 million to help accelerate discovery of next-generation mitochondrial […]